Background
The need for opioid analgesics with reduced undesirable side-effects has initiated a vast amount of scientific efforts, which have led to a number of new opioid ligands and significant expansion of knowledge in opioid pharmacology. The development of morphinans anellated with heterocycles gave rise to several potential therapeutic agents and useful pharmacological tools.
Methods
The chemistry involved the design and synthesis of two sets of oxazolomorphinans having the new heteroring anellated to the A-ring of the morphinan backbone. Binding affinities of the newly synthesized compounds at opioid receptors were determined by in vitro competition binding assays using rat brain (μ, δ) and guinea pig brain () 
Results
Binding studies on the newly synthesized N-methyl and N-allyl derivatives to opioid receptors revealed remarkable results for three compounds: the aminosubstituted N-methyloxazolomorphinan showed high affinity and selectivity to the μ opioid receptor, while two N-allyloxazolomorphinans were found to interact with high affinity with μ and sites and moderate binding towards δ receptors. In ligand-stimulated [ 35 S] GTPγS binding studies, the N-methyl congener acted as a potent and full agonist at the μ receptor. The two N-allyl derivatives showed antagonistic effects at μ and receptors.
Conclusions
The design and synthesis of novel oxazolomorphinans led to an interesting alteration in opioid activity by influencing the biological and pharmacological profile of these compounds interacting with μ, δ and opioid receptors.
